NOTV: Inotiv Corporation Company Value to Net Income

Inotiv, Inc. (NOTV) relies on a network of European and American laboratories, which stabilizes testing timelines. The asset's valuation trend on GURU.Markets, reaching 0.00, contrasts with the geopolitical barriers hindering the cross-border exchange of biomaterials. Meanwhile, long-term agreements with industry behemoths guarantee cash inflows, confirming high operational efficiency and the relevance of the provided services.

NOTV: Inotiv Corp P/E Multiple 07/04/2022 - 06/13/2026

Analytical breakdowns for Inotiv Corp (NOTV)

- price and consensus price forecast:

Stock Price inotivco.com|NOTV - Consensus Target

- market capitalization information:

Market Value Inotiv, Inc.|NOTV - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Book Price of a Share Inotiv|NOTV - Book Capitalization|Market-to-Book Ratio inotivco.com|NOTV - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

NOTV - Company Net Income|Expected Net Profit Inotiv, Inc.|NOTV - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Inotiv Inc|NOTV - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Inotiv, Inc.|NOTV - Operating profit before deduction of amortization|Earnings per share for the last twelve months Inotiv|NOTV - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months inotivco.com|NOTV - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Inotiv, Inc.

Comprehensive company analysis:Inotiv, Inc.

The ratio of market capitalization to net income measures the investment payback period, revealing gaps between stock quotes and the actual profitability of the business. By analyzing the P/E fundamental multiple of Inotiv, Inc. (NOTV), an investor assesses the extent to which the market overvalues the unique expertise of Inotiv, Inc. (NOTV) in preclinical research, which is critically important for startups seeking to accelerate the time-to-market for their drugs.

Key competitors